Adina-Bianca Foșălău

Dr. Adina-Bianca Foșălău

Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGeorgiana Diana Cazac-Panaite
Georgiana Diana Cazac-Panaite
CLCristina-Mihaela Lăcătușu
Cristina-Mihaela Lăcătușu
EGELENA-DANIELA GRIGORESCU
ELENA-DANIELA GRIGORESCU
AFAdina-Bianca Foșălău
Adina-Bianca Foșălău
AOAlina Onofriescu
Alina Onofriescu
Bogdan-Mircea MihaiBogdan-Mircea Mihai
Bogdan-Mircea Mihai
Metabolic dysfunction-associated steatotic liver disease (MASLD), a progressive liver disease frequently associated with metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity, has the potential to progress symptomatically to liver cirrhosis and, in some cases, hepatocellular carcinoma. Hence, an urgent need arises to identify and approve new therapeutic options to improve patient outcomes. Research efforts have focused on either developing dedicated molecules or repurposing drugs already approved for other conditions, such as metabolic diseases. Among the latter, antidiabetic and anti-obesity agents have received the most extensive attention, with pivotal trial results anticipated shortly. However, the primary focus underlying successful regulatory approvals is demonstrating a substantial efficacy in improving liver fibrosis and preventing or ameliorating cirrhosis, the key advanced outcomes within MASLD progression. Besides liver steatosis, the ideal therapeutic candidate should reduce inflammation and fibrosis effectively. Although some agents have shown promise in lowering MASLD-related parameters, evidence of their impact on fibrosis and cirrhosis remains limited. This review aims to evaluate whether antidiabetic and anti-obesity drugs can be safely and effectively used in MASLD-related advanced fibrosis or cirrhosis in patients with T2DM. Our paper discusses the molecules closest to regulatory approval and the expectation that they can address the unmet needs of this increasingly prevalent disease.

15 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EGELENA-DANIELA GRIGORESCU
ELENA-DANIELA GRIGORESCU
Bogdan-Mircea MihaiBogdan-Mircea Mihai
Bogdan-Mircea Mihai
GCGeorgiana Diana Cazac-Panaite
Georgiana Diana Cazac-Panaite
AFAdina-Bianca Foșălău
Adina-Bianca Foșălău
AOAlina Onofriescu
Alina Onofriescu
CLCristina-Mihaela Lăcătușu
Cristina-Mihaela Lăcătușu
Background: Asymptomatic left ventricular diastolic dysfunction (LVDD) occurs in type 2 diabetes mellitus (T2DM) patients, particularly among the elderly. Aim: This study aimed to identify diastolic function changes over a 52-week follow-up and the predictive factors for LVDD in T2DM patients without atherosclerotic manifestations. Methods: Diastolic function, metabolic profile, atherogenic indexes, and subclinical inflammatory markers were assessed at baseline and after one year in 138 T2DM outpatients. All variables were compared in patients with and without LVDD across three age groups. Results: The patients were 57.86 ± 8.82 years old, 49.3% male, with a mean 5-year diabetes duration and a median HbA1c of 7.8%. At baseline, 71 patients had grade 1 LVDD, 12 had grade 2 and 3 LVDD, and 15 had indeterminate LVDD. In the elderly group, 29 patients had LVDD. The logistic regression analysis identified age over 65 as an independent risk factor for LVDD (Exp B = 9.85, 95% CI: 1.29–75.36, p = 0.027). LVDD patients had a longer diabetes duration and a higher prevalence of diabetic neuropathy. Elderly patients had the lowest E/A, e’, lateral s’, atherogenic and Castelli risk indexes, and significantly higher E/e’, EDT, LAVI and TNF-alpha values (p < 0.05). After 52 weeks, diastolic function worsened in 27 patients, who had no significant differences compared to those with stable or improved diastolic function. Conclusions: LVDD was common in our T2DM patients without known cardiovascular disease, and age increases the LVDD risk. Echocardiographic assessment is necessary, especially in elderly T2DM patients with co-morbidities, to identify patients at risk of progression to heart failure early.